NextBio

Help
Description: Candesartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Candesartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.
Drug Type: Small Molecule; Approved; Investigational
Pharmacology: Candesartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Unlike the angiotensin receptor antagonist losartan, Candesartan does not have an active metabolite or possess uricosuric effects.
Mechanism of Action: Candesartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.
Indication: For the treatment of hypertension.
Half Life: Approximately 9 hours.
View Complete Description



Data Correlations | 2 studies

Help for Data Correlations View All
Genes category icon Genes
Score Help
AGTR1 100 100
RGD1563244_predicted 99 99
BCMO1 95 95
Rapgef1 94 94
H1FX 91 91
ABHD8 90 90
View Top Genes
Biogroups category icon Biogroups
Score Help
Retinol Metabolism 100 100
ACE Inhibitor Pathway 94 94
ADP-Ribosylation Factor Pathway 93 93
Ricin B-related lectin 92 92
Ricin B lectin 92 92
ACE2 Pathway 92 92
View Top Biogroups

Individual Studies

  • Drug target sets for approved compounds

    Homo sapiens Homo sapiens | Therapeutic   Therapeutic

    The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

    Authors: David S Wishart, Craig Knox, An Chi Guo et al.

    Organization: Department of Computing Science, Univers…

  • Ischemic brain from candesartan or vehicle pre-treated rats

    Rattus norvegicus Rattus norvegicus | RNA Expression   RNA Expression

    Ischemic brain areas of Candesartan pre-treated (0,2 mg/kg bwt., 5 days, s.c.) versus vehicle treated, normotensive, adult rats after middle carotid artery occlusion (MCAO).

    Authors: Thone-Reineke Christa, Ungethuem Ute, Witt Henning et al.

    Organization: Max Planck Institute for Molecular Genet…
View All Individual Studies

Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving candesartan.

View All Author iconAuthors
  • Salim Yusuf
  • Marc A Pfeffer
  • Karl Swedberg
  • Christopher B Granger
  • John J V McMurray
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • AstraZeneca
  • Norwegian University of Science and Technology
  • Dresden University of Technology
  • City Hospitals Sunderland NHS Foundation Trust
  • Asker & Baerum Hospital
View All Affiliations icon Organizations
  • University of Glasgow
  • Western Infirmary
  • Brigham and Women's Hospital
  • Gachon Medical School
  • Kumamoto University Graduate School of Medical Sciences

Clinical Trials | 92 trials

Help for Clinical Trials View All

Community

Help for Community
NextBio Users

  • No NextBio users were found for “candesartan”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

View All NextBio Groups | 1 group

© 2010 NextBio